Refine your search:     
Report No.
 - 
Search Results: Records 1-8 displayed on this page of 8
  • 1

Presentation/Publication Type

Initialising ...

Refine

Journal/Book Title

Initialising ...

Meeting title

Initialising ...

First Author

Initialising ...

Keyword

Initialising ...

Language

Initialising ...

Publication Year

Initialising ...

Held year of conference

Initialising ...

Save select records

JAEA Reports

XAFS measurement of simulated waste glass samples (Borosilicate glass including vanadium)

Nagai, Takayuki; Kobayashi, Hidekazu; Sasage, Kenichi; Ayame, Yasuo; Okamoto, Yoshihiro; Shiwaku, Hideaki; Matsuura, Haruaki*; Uchiyama, Takafumi*; Okada, Yukiko*; Nezu, Atsushi*; et al.

JAEA-Research 2016-015, 52 Pages, 2016/11

JAEA-Research-2016-015.pdf:37.48MB

The local structure of waste elements in simulated waste glasses including V was estimated by using synchrotron XAFS measurement in this study. The results are as follows. (1) V has a high possibility which exists in the glass phase in the case of frit, and V can regard both samples as stable 4 coordination structure. (2) Zn, Ce, Nd, Zr, and Mo exist in the glass phase, and the difference is admitted by the percentage of Ce(III) and Ce(IV) by the composition. (3) Ru is separated from the glass phase as RuO$$_{2}$$ crystalline, both of metal and oxide exist in Rh, and Pd is separated out as metal. (4) It was confirmed that the regularity of the local structure of Zr and Mo in the molten glasses retreats as a result of the XAFS measurement at high temperature. (5) The XAFS measurement of molten glasses were performed at 1200$$^{circ}$$C, so it would be possible to acquire excellent data by improving the shapes of the sample cell.

Journal Articles

Preparation and evaluation of $$^{186/188}$$Re-labeled antibody (A7) for radioimmunotherapy with rhenium(I) tricarbonyl core as a chelate site

Ogawa, Kazuma*; Kawashima, Hidekazu*; Kinuya, Seigo*; Shiba, Kazuhiro*; Onoguchi, Masahisa*; Kimura, Hiroyuki*; Hashimoto, Kazuyuki; Odani, Akira*; Saji, Hideo*

Annals of Nuclear Medicine, 23(10), p.843 - 848, 2009/12

 Times Cited Count:9 Percentile:33.73(Radiology, Nuclear Medicine & Medical Imaging)

Rhenium is one of the most valuable elements for internal radiotherapy because $$^{186/188}$$Re have favorable physical characteristics. However, there are problems when proteins such as antibodies are used as carriers of $$^{186/188}$$Re. Labeling methods require the complicated processes. Therefore, we planned the preparation by a simple method and evaluation of a stable $$^{186/188}$$Re-labeled antibody. For this purpose, we selected $$^{186/188}$$Re(I) tricarbonyl complex as a chelating site. A7 was used as a model protein. $$^{186/188}$$Re-labeled A7 was prepared by directly reacting a $$^{186/188}$$Re(I) tricarbonyl precursor with A7. $$^{186/188}$$Re-(CO)$$_{3}$$-A7 were prepared with radiochemical yields of 23-28%. After purification, $$^{186/188}$$Re-(CO)$$_{3}$$-A7 showed a radiochemical purity of over 95%. In biodistribution experiments, $$^{186/188}$$Re-labeled A7 showed high uptakes in the tumor.

Journal Articles

Therapeutic effects of a $$^{186}$$Re-complex-conjugated bisphosphonate for the palliation of metastatic bone pain in an animal model

Ogawa, Kazuma*; Mukai, Takahiro*; Asano, Daigo*; Kawashima, Hidekazu*; Kinuya, Seigo*; Shiba, Kazuhiro*; Hashimoto, Kazuyuki; Mori, Hirofumi*; Saji, Hideo*

Journal of Nuclear Medicine, 48(1), p.122 - 127, 2007/01

We developed a highly stable rhenium-186 ($$^{186}$$Re)-MAG3 complex-conjugated bisphosphonate, ($$^{186}$$Re-MAG3-HBP), for the treatment of painful bone metastases. This agent showed a superior biodistribution as a bone-seeking agent in normal mice when compared with $$^{186}$$Re-HEDP. In this study, we evaluated the therapeutic effects of $$^{186}$$Re-MAG3-HBP using an animal model of bone metastasis. In the rats treated with $$^{186}$$Re-HEDP, tumor growth was comparable to that in untreated rats. In contrast, when $$^{186}$$Re-MAG3-HBP was administered, tumor growth was significantly inhibited. Allodynia induced by bone metastasis was attenuated by treatment with $$^{186}$$Re-MAG3-HBP or $$^{186}$$Re-HEDP, but $$^{186}$$Re-MAG3-HBP tended to be more effective. These results indicate that $$^{186}$$Re-MAG3-HBP could be useful as a therapeutic agent for the palliation of metastatic bone pain.

Oral presentation

Therapeutic effects of a new $$^{186}$$Re-labeled bisphosphonate in a rat model of bone metastasis

Ogawa, Kazuma*; Mukai, Takahiro*; Asano, Daigo*; Kawashima, Hidekazu*; Hashimoto, Kazuyuki; Shiba, Kazuhiro*; Mori, Hirofumi*; Saji, Hideo*

no journal, , 

no abstracts in English

Oral presentation

Preparation of $$^{188}$$Re-labeled antibody (A7) by a simple method using rhenium(I) tricarbonyl complex

Ogawa, Kazuma*; Kawashima, Hidekazu*; Kinuya, Seigo*; Yoshimoto, Mitsuyoshi*; Shiba, Kazuhiro*; Kimura, Hiroyuki*; Hashimoto, Kazuyuki; Mori, Hirofumi*; Saji, Hideo*

no journal, , 

$$^{188}$$Re is one of the most useful radionuclides for internal radiotherapy. However, there is a problem when protein such as antibody is used as a carrier of $$^{188}$$Re. The labeling method using bifunctional chelating agents require the conjugation of $$^{188}$$Re-complex to protein after radiolabeling with the bifunctional chelating agent. Then, we planned the preparation of a stable $$^{188}$$Re-labeled protein by a simple method. A7 monoclonal antibody was labeled by reacting $$^{188}$$Re(I) tricarbonyl precursor with A7 directly. $$^{188}$$Re labeled A7 was prepared with radiochemical yield of 23%. After purification, $$^{188}$$Re labeled A7 showed radiochemical purity over 98%. After 24 hours of incubation, about 93% of $$^{188}$$Re-A7 remained intact, which indicates $$^{188}$$Re-A7 is stable in vitro. In biodistribution experiment, 11.2% of the injected dose/g of $$^{188}$$Re-A7 accumulated in the tumor at 24 hours postinjection, and tumor to blood ratio was over 1.0 at the same time.

Oral presentation

Synthesis and evaluation of $$^{186}$$Re-labeled biotin as a labeling agent for antibodies

Hirasawa, Makoto*; Kawashima, Hidekazu*; Ogawa, Kazuma*; Kimura, Hiroyuki*; Ono, Masahiro*; Hashimoto, Kazuyuki; Saji, Hideo*

no journal, , 

no abstracts in English

Oral presentation

Pretargeted radioimmunotherapy of tumor using a novel radiorhenium-labeled biotin derivative and streptavidin conjugated anti-cytokeratin 19 monoclonal antibody

Kawashima, Hidekazu*; Hirasawa, Makoto*; Kimura, Hiroyuki*; Ono, Masahiro*; Hashimoto, Kazuyuki; Saji, Hideo*

no journal, , 

no abstracts in English

Oral presentation

Research and development for next generation vitrification technology by using synchrotron radiation based analytical technique

Okamoto, Yoshihiro; Shiwaku, Hideaki; Nagai, Takayuki; Kobayashi, Hidekazu; Sasage, Kenichi; Kawashima, Hidenori*; Kakihara, Toshiaki*

no journal, , 

The vitrification technique is thought to be effective in immobilization of high-level radioactive liquid waste (HLLW). To the nuclear waste glass, higher waste loading and low leach rate are required. Synchrotron radiation based X-ray absorption fine structure (XAFS) analysis is useful to investigate the local coordination structure and chemical state of the FP component in the waste glass, since many kinds of elements more than 30 are contained in the glass. We have analyzed many glass samples by using JAEA beamline facility at the SPring-8, in conjunction with many coworkers. Since FY2016, we joined the Research and Development program for next generation reprocessing and vitrification technology carried out by assistance of Agency of Natural Resources and Energy (METI). Synchrotron radiation based XAFS work on the improvement activity of borosilicate glass system and substitute to iron phosphate glass system carried out in the program are introduced in this presentation.

8 (Records 1-8 displayed on this page)
  • 1